Prognostic Significance of the Gustave-Roussy Immune Score in Colon Cancer Patients Treated with Adjuvant CAPEOX Regimen
Kadriye Bir Yucel1, Osman Sutcuoglu1, Tuba Ugur2, Cisem Cagdaser2, Ozan Yazici1, Ahmet Ozet1, Nuriye Ozdemir11Department of Medical Oncology, Gazi University, Ankara, Türkiye, 2Department of Internal Medicine, Gazi University, Ankara, Türkiye
Objectives: The aim of this research was to assess the prognostic value of Gustave-Roussy immune score (GRIm-Score) in stage II and III colon cancer patients receiving capecitabine and oxaliplatin (CAPEOX). Methods: Serum lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and albumin levels were used to create the GRIm-Score. The GRIm-score was obtained with the sum of these three laboratory parameters, which were scored as 0 and 1 according to the cut-off values. A homogeneous patient group (high-risk stage II and stage III patients) was classified into two groups, one with a high GRIm-Score (score 2 and 3) and the other with a low GRImScore (score 0 and 1). Results: The 4-year recurrence-free survival (RFS) was 60% in the GRIm-Score high group and 94.4% in the GRIm-Score low group (p<0.001). The 4-year overall survival (OS) was 78.1% in the GRIm-Score high group and 93.8% in the GRImScore low group (p<0.001). Additionally, multivariable analyses revealed that GRIm-Score (HR: 4.226, 95% CI: 1.953- 9.143, p <0.001) was an independent prognostic marker for OS. Conclusion: High GRIm-Score was significantly related to poor OS in stage II and III colon cancer patients who received CAPEOX. Keywords: Colon cancer, survival, immune score, prognosis
Cite This Article
Yucel K, Sutcuoglu O, Ugur T, Cagdaser C, Yazici O, Ozet A, Ozdemir N. Prognostic Significance of the Gustave-Roussy Immune Score in Colon Cancer Patients Treated with Adjuvant CAPEOX Regimen. EJMI. 2023; 7(4): 433-439
Corresponding Author: Kadriye Bir Yucel